IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.542
AS - Asia 13.546
EU - Europa 12.751
SA - Sud America 3.220
Continente sconosciuto - Info sul continente non disponibili 380
AF - Africa 346
OC - Oceania 29
Totale 57.814
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.910
SG - Singapore 4.724
IT - Italia 4.244
CN - Cina 3.305
RU - Federazione Russa 3.206
BR - Brasile 2.513
VN - Vietnam 1.926
GB - Regno Unito 1.446
BD - Bangladesh 1.056
HK - Hong Kong 951
CA - Canada 947
DE - Germania 831
FR - Francia 509
UA - Ucraina 471
SE - Svezia 429
FI - Finlandia 336
IN - India 327
IE - Irlanda 272
AR - Argentina 251
MX - Messico 250
NL - Olanda 211
TR - Turchia 187
PL - Polonia 183
ID - Indonesia 170
ES - Italia 138
IQ - Iraq 137
EC - Ecuador 128
ZA - Sudafrica 126
DK - Danimarca 123
IL - Israele 120
JP - Giappone 119
PK - Pakistan 99
CO - Colombia 88
AT - Austria 84
CR - Costa Rica 74
VE - Venezuela 63
UZ - Uzbekistan 61
MA - Marocco 57
AE - Emirati Arabi Uniti 54
HN - Honduras 54
LT - Lituania 52
GT - Guatemala 48
PY - Paraguay 47
SV - El Salvador 45
CL - Cile 44
TT - Trinidad e Tobago 44
PR - Porto Rico 43
PE - Perù 36
SA - Arabia Saudita 36
PH - Filippine 34
MY - Malesia 32
NI - Nicaragua 32
EG - Egitto 31
KE - Kenya 29
TN - Tunisia 29
CH - Svizzera 27
CW - ???statistics.table.value.countryCode.CW??? 25
JM - Giamaica 25
UY - Uruguay 23
AZ - Azerbaigian 22
DZ - Algeria 22
BO - Bolivia 21
EU - Europa 21
BE - Belgio 20
JO - Giordania 20
NP - Nepal 20
GP - Guadalupe 19
AU - Australia 18
KZ - Kazakistan 16
RO - Romania 16
AL - Albania 14
DO - Repubblica Dominicana 14
OM - Oman 13
TH - Thailandia 13
CZ - Repubblica Ceca 12
TW - Taiwan 12
PA - Panama 11
SK - Slovacchia (Repubblica Slovacca) 11
AM - Armenia 10
GR - Grecia 10
HU - Ungheria 10
IR - Iran 10
BB - Barbados 9
PT - Portogallo 9
BY - Bielorussia 8
KW - Kuwait 8
LB - Libano 8
MC - Monaco 8
NZ - Nuova Zelanda 8
PS - Palestinian Territory 8
BG - Bulgaria 7
MD - Moldavia 7
SN - Senegal 7
BH - Bahrain 6
CG - Congo 6
ET - Etiopia 6
GE - Georgia 6
HR - Croazia 6
KR - Corea 6
LV - Lettonia 6
Totale 57.346
Salva come PNG Salva come JPEG
Città #
Dallas 4.556
Singapore 2.472
San Jose 1.910
Ashburn 1.827
Chicago 1.326
Beijing 1.273
Council Bluffs 1.184
Los Angeles 1.166
Hong Kong 880
Ho Chi Minh City 614
Moscow 588
Milan 582
Salt Lake City 558
Southend 540
New York 539
Buffalo 478
Chandler 453
Fairfield 416
Rome 387
Hanoi 380
Houston 362
Santa Clara 358
Woodbridge 335
San Mateo 332
Tampa 315
Wilmington 290
The Dalles 287
Seattle 285
Phoenix 279
São Paulo 267
Dublin 258
Elk Grove Village 251
Ann Arbor 243
Cambridge 243
Falls Church 232
Lauterbourg 231
Boardman 222
Hefei 221
Helsinki 208
Ottawa 200
Jacksonville 195
Montreal 171
Pisa 170
Dearborn 162
Beauharnois 156
Portsmouth 156
Warsaw 155
Orem 153
Florence 147
Munich 142
Stevenage 142
Brooklyn 131
Naples 126
Sterling 124
Mexico City 121
Frankfurt am Main 119
Dong Ket 117
Lancaster 117
London 117
Toronto 110
Atlanta 109
Lawrence 107
Miami 106
Tel Aviv 104
Denver 103
Tokyo 101
Poplar 93
Amsterdam 92
Istanbul 90
Chennai 87
Rio de Janeiro 87
Johannesburg 84
Bologna 81
Stockholm 81
Da Nang 78
Nuremberg 78
Columbus 73
Turin 73
Dulles 72
Washington 65
Palermo 63
Detroit 62
San Diego 60
Haiphong 59
Figino 58
Manchester 58
Belo Horizonte 57
Boston 56
Kansas City 56
San José 56
Tashkent 56
Genoa 54
Lappeenranta 53
Charlotte 50
Bari 48
Turku 48
Brasília 47
San Francisco 47
Baghdad 44
Quito 44
Totale 33.219
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.863
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.733
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.610
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 752
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 712
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 633
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 485
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 435
A simple echocardiographic score to rule out cardiac amyloidosis 433
A simple echocardiographic score to rule out cardiac amyloidosis 412
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 402
The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians 396
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 350
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 350
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 343
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 337
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 336
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 335
Adrenergic activation in heart failure: blockade or rebalance? 326
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 326
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 325
Eligibility for vericiguat in a real‐world, contemporary heart failure population 323
[Ten perspectives for research and innovation in cardiac amyloidosis] 320
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 316
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 316
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 316
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 315
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 315
RNA-targeting and gene editing therapies for transthyretin amyloidosis 314
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 314
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 314
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 312
Screening the health status of people working in a university 305
Sex-related differences in chronic heart failure 302
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 302
How to take arms against central apneas in heart failure 301
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 301
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 298
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 298
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 294
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 293
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 291
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 289
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 288
Cardiac light-chain deposition disease relapsing in the transplanted heart 286
Cardiac magnetic resonance findings and prognosis in type 1 myotonic dystrophy 283
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 283
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 283
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 282
Atrial amyloidosis: mechanisms and clinical manifestations 280
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 280
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 280
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 278
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 276
Biomarkers for the diagnosis and management of heart failure: New frontiers 276
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 275
Biomarkers for the diagnosis and management of heart failure 274
Update sui biomarcatori nello scompenso cardiaco. 273
Valve disease in cardiac amyloidosis: an echocardiographic score 271
Disease features and management of cardiomyopathies in women 271
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 269
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) 269
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 268
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 263
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 261
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 261
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 260
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 259
null 258
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 258
Renin profiling predicts neurohormonal response to sacubitril/valsartan 258
The search for efficient diagnostic and prognostic biomarkers of heart failure 256
Role of Imaging in Cardiomyopathies 255
null 253
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 252
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 251
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study 250
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 250
Valvular heart disease in patients with cardiac amyloidosis 248
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 248
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 243
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 243
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 243
Cardiac Amyloidosis: How Its Epidemiology is Changing 242
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 242
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 240
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 240
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 240
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies 239
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 238
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 238
Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis 238
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 237
Prognostic value of plasma Renin activity in heart failure. 237
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 237
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 237
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 236
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 236
Cardiac amyloidosis: Innovations in diagnosis and treatment 235
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 235
Totale 34.305
Salva come PNG Salva come JPEG
Categoria #
all - tutte 273.420
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 273.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.394 0 0 0 198 75 69 202 338 142 199 36 135
2022/20231.348 110 112 62 143 166 178 36 120 253 30 83 55
2023/20241.338 76 36 239 102 73 120 105 65 51 75 55 341
2024/202513.757 112 134 492 202 421 496 1.194 2.132 818 1.995 3.124 2.637
2025/202629.429 1.464 4.071 3.936 3.830 2.783 1.795 2.691 1.329 1.783 1.903 2.013 1.831
2026/20275.251 769 909 1.722 1.851 0 0 0 0 0 0 0 0
Totale 57.814